Suzhou Fengbei Biotech Stock Co., Ltd. (603334.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 30.25

From 52W high−53.24%

Volume2.26M

Market capCNY 4.48B

P/E (TTM)31.9x

P/S (TTM)1.2x

Div yield1.11%

Key dataSep 18, 2026

Open

CNY 30.25

From 52W high

−53.24%

Volume

2.26M

Market cap

CNY 4.48B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.7x

P/E (TTM)

31.9x

RSI (14)

49.2

MomentumView details →

1D Return

−4.44%

YTD Return

−24.76%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

31.9x

EV/EBITDA

21.7x

EV/Sales

1.1x

P/S (TTM)

1.2x

P/B (TTM)

2.6x

ProfitabilityView details →

Gross Margin

7.17%

Net Margin

4.01%

EBITDA Margin

5.07%

ROE (TTM)

8.32%

ROA (TTM)

6.68%

Asset Turnover

1.65x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+22.89%

EPS CAGR 3Y

−0.53%

EBITDA YoY

—

MomentumView details →

1D Return

−4.44%

YTD Return

−24.76%

1Y Return

—

RSI (14)

49.2

vs 50D SMA

−1.40%

vs 200D SMA

−27.44%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

4.03x

Quick Ratio

2.94x

Div Yield

1.11%

Div Rate

CNY 0.35

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

3.61B

Net Income (TTM)

144.76M

Op. CF (TTM)

88.64M

Latest newsMore news →

Fengbei Biotech announced its H1 2026 results: revenue of 2.347 billion yuan, up 58.76% year-on-year; net profit attributable to shareholders of 81.4251 million yuan, down 4.28% year-on-year.28d ago

Similar companies

Amicus Therapeutics, Inc.FOLD Veradermics, IncorporatedMANE Adaptive Biotechnologies CorporationADPT Iovance Biotherapeutics, Inc.IOVA Jacobio Pharmaceuticals Group Co., Ltd.01167.HK ACADIA Pharmaceuticals Inc.ACAD Find similar companies →

Latest newsMore news →

Fengbei Biotech announced its H1 2026 results: revenue of 2.347 billion yuan, up 58.76% year-on-year; net profit attributable to shareholders of 81.4251 million yuan, down 4.28% year-on-year.28d ago